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Abstract
Aims/hypothesis Pancreatic cell development is a tightly con-
trolled process. Although information is available regarding
the mesodermal signals that control pancreatic development,
little is known about the role of environmental factors such as
nutrients, including glucose, on pancreatic development. We
previously showed that glucose and its metabolism through
the hexosamine biosynthesis pathway (HBP) promote pancre-
atic endocrine cell differentiation. Here, we analysed the role
of the transcription factor carbohydrate-responsive element-
binding protein (ChREBP) in this process. This transcription
factor is activated by glucose, and has been recently described
as a target of the HBP.
Methods We used an in vitro bioassay in which pancreatic
endocrine and exocrine cells develop from rat embryonic
pancreas in a way that mimics in vivo pancreatic develop-
ment. Using this model, gain-of-function and loss-of-
function experiments were undertaken.
Results ChREBP was produced in the endocrine lineage dur-
ing pancreatic development, its abundance increasing with
differentiation. When rat embryonic pancreases were cultured
in the presence of glucose or xylitol, the production of
ChREBP targets was induced. Concomitantly, beta cell dif-
ferentiation was enhanced. On the other hand, when embry-
onic pancreases were cultured with inhibitors decreasing
ChREBP activity or an adenovirus producing a dominant-
negative ChREBP, beta cell differentiation was reduced, indi-
cating that ChREBP activity was necessary for proper beta
cell differentiation. Interestingly, adenovirus producing a
dominant-negative ChREBP also reduced the positive effect
of N-acetylglucosamine, a substrate of the HBP acting on beta
cell differentiation.
Conclusions/interpretation Our work supports the idea that
glucose, through the transcription factor ChREBP, controls
beta cell differentiation from pancreatic progenitors.
Keywords Carbohydrate-responsive element-binding
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The mature pancreas contains exocrine acinar cells that
secrete digestive enzymes into the intestine, and endocrine
islets that synthesise hormones such as insulin (beta cells),
glucagon (alpha cells), somatostatin (delta cells) and pan-
creatic polypeptide (PP cells). The pancreas originates from
the dorsal and ventral regions of the foregut endoderm
directly posterior to the stomach. The first indication of
pancreatic morphogenesis occurs in mice at embryonic day
(E) 8.5 (E9.5 in rat), when the endoderm evaginates to form
buds. Subsequently, the mesenchyme condenses around the
underlying endoderm and the epithelial buds grow in size,
while the exocrine and endocrine cells differentiate [1].
During development, the endodermal region committed
to form the pancreas initially produces the transcription
factor pancreatic and duodenal homeobox 1 (Pdx-1), a
marker of pancreatic progenitors also produced in mature
beta cells [2]. The basic helix–loop–helix factor neurogenin
3 (Neurog3) is then transiently produced in epithelial pan-
creatic progenitor cells prior to endocrine differentiation [3].
Neurog3 controls the expression of NeuroD, which is an-
other member of the basic helix–loop–helix transcription
factor family [4].
Pancreatic development is controlled by signals derived
from tissues in contact with the endodermal region that
gives rise to the pancreas [5]. Pancreatic development also
depends on environmental signals such as oxygen tension
[6, 7] and nutrients [8]. We previously showed that glucose
controls beta cell development [9]. Specifically, we found
that glucose favours pancreatic endocrine cell development
by regulating the transition between Neurog3 and NeuroD
[9].
Typically, glucose is transported inside the cell and is
phosphorylated into glucose 6-phosphate. It next enters three
pathways: the glycolysis pathway to provide energy, the hex-
osamine biosynthetic pathway (HBP) and the pentose phos-
phate pathway [10]. We previously demonstrated that the
positive effect of glucose on beta cell development required
its metabolism through the HBP [11]. This pathway produces
UDP-N-acetyl-glucosamine (UDP-GlcNAc), a substrate for
N- and O-glycosylation, as well as for O-GlcNAcylation,
which consists of the addition of a single GlcNAc moiety to
serine and threonine residues (for a review, see Bouche et al
[12]). This last modification is highly dynamic and often
compared with phosphorylation.
Interestingly, the pentose phosphate pathway is an alterna-
tive pathway for glucose metabolism that generates NADPH
and synthesises pentose sugars [13]. Xylulose 5-phosphate, an
intermediate of the pentose phosphate pathway, activates type
2A protein phosphatase (PP2A), which in turn dephosphor-
ylates and activates transcription factor carbohydrate-
responsive element binding protein (ChREBP) [14, 15].
ChREBP is a transcription factor that belongs to the basic
helix–loop–helix leucine zipper family, which transactivates
glucose-responsive genes such as those encoding acetyl-
CoA carboxylase (ACCase) and liver-type pyruvate kinase
(L-PK) by binding the carbohydrate-responsive element
[16]. To the best of our knowledge, little information is
available concerning the role of ChREBP in pancreatic cell
development.
Here, we tested the possible involvement of ChREBP in
pancreatic development, and the role of ChREBP as a me-
diator of glucose effect on beta cell differentiation. For this
purpose, we modulated ChREBP activity in an in vitro
model of pancreatic development and analysed beta cell
differentiation.
Methods
Animals and dissection of dorsal pancreatic rudiments Preg-
nant Wistar rats were purchased from CERJ (Le Genest, St
Isle, France). The first day post-coitum was designated
embryonic day 0.5 (E0.5). Pregnant rats at 13.5 days of
gestation were killed by carbon dioxide asphyxiation in
compliance with the French Animal Care Committee’s
guidelines. Dorsal pancreatic buds from E13.5 rat embryos
were dissected as previously described [17]. Pancreases
from E18.5 WT or Neurog3–/– mice were dissected and used
for RNA extraction.
Organ culture, PP2A inhibitor treatments and BrdU incor-
poration Pancreases were laid on 0.45 μm filters (Millipore,
St-Quentin-en-Yvelines, France) at the air–medium interface
in Petri dishes containing RPMI 1640 (Lonza, Basel, Swit-
zerland) supplemented with penicillin (100 U/ml), strepto-
mycin (100 μg/ml), HEPES (10 mmol/l), non-essential
amino acids (1X; Invitrogen, Cergy-Pontoise, France) and
10% heat-inactivated FCS (HyClone, Logan, UT, USA)
(complete RPMI culture medium) [18]. Cultures were main-
tained at 37°C in humidified 95% air–5% CO2. D-Glucose,
xylitol, okadaic acid, calyculin A and GlcNAc (Sigma-
Aldrich, Lyon, France) were used at the indicated concen-
trations. It has to be noted that, in the medium without added
glucose, about 1 mmol/l glucose is added by the serum. The
medium was changed every other day. For cell proliferation
assays, 10 μmol/l BrdU (Sigma-Aldrich) was added to the
medium during the last hour of culture. At the end of the
indicated culture period, the pancreatic rudiments were
photographed.
Pancreatic dissociation and adenoviral infection Pan-
creases were dissected and kept in PBS–2% FCS, before
being resuspended in 500 μl Hank’s balanced salt solution
(HBSS) containing collagenase V (1 mg/ml) and DNase
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(20 μg/ml) (both from Sigma-Aldrich). The dissociation
was performed at 37°C in a thermomixer (Eppendorf, Le
Pecq, France). At the end of the dissociation, complete
RPMI culture medium was added to the cell suspension
which was then centrifuged for 1 min at 2,000g. The cells
were washed three times and divided into aliquots in 1.5 ml
tubes (5×104 cells/tube) in 500 μl complete RPMI culture
medium supplemented with ROCK inhibitor (7 μg/ml;
Sigma-Aldrich). The tubes were centrifuged for 1 min at
2,000g and kept open overnight in the incubator. During this
period, cells reaggregated and formed clusters that were
transferred on a filter and cultured for 6 further days in
complete RPMI culture medium supplemented with ROCK
inhibitor. For adenoviral infection, dissociated cells were
cultured in 50 μl RPMI 1640 with adenoviruses (multiplic-
ity of infection of two) producing a dominant-negative
ChREBP (also known as Mlxipl) into the basic region of
the DNA binding domain (dnChREBP) [19], or green fluo-
rescent protein (GFP) as a control for 2 h 30 min at 37°C. At
the end of the infection period, 500 μl complete RPMI
medium was added, and cells were centrifuged for 1 min
at 3,000 rpm and reaggregated as described above, before
being transferred on a floating filter for 6 days.
Immunohistochemistry Tissues were fixed in 10% formalin,
pre-embedded in low-gelling agarose, and embedded in par-
affin. All sections (4 μm thick) of each pancreatic explant
were collected and processed for immunohistochemical anal-
ysis as previously described [20, 21]. Antibodies were used in
the following dilutions: mouse anti-insulin, 1/2,000; rabbit
anti-insulin, 1/2,000; rabbit anti-amylase, 1/300 (all from
Sigma-Aldrich); rabbit anti-proconvertase 1/3 (PC1/3),
1/1,000 (gift from Dr Steiner, University of Chicago, IL,
USA); mouse anti-synaptophysin, 1/10 (Dako, Trappes,
France); rabbit anti-PDX1 T1/1,000 T[22]; mouse anti-GFP,
1/500 (Euromedex, Souffelweyersheim, France); mouse anti-
BrdU, 1/4 (AmershamBiosciences, Amersham, Buckingham-
shire, UK). The fluorescent secondary antibodies used includ-
ed fluorescein anti-rabbit and Texas red anti-mouse antibodies
(both from Jackson ImmunoResearch, Newmarket, Suffolk,
UK) and Alexa Fluor 488 anti-rabbit antibody (Invitrogen).
Nuclei were stained with Hoechst 33342 (0.3 μg/ml;
Invitrogen).
TUNEL experiments were performed using an in situ
cell death detection kit (Roche, Neuilly-sur-Seine,
France), following the manufacturer’s instructions, on
pancreases cultured for 7 days in the presence of glu-
cose 10 mmol/l or xylitol 10 mmol/l alone or supple-
mented with okadaic acid or calyculin A at the
indicated concentrations. Results are expressed as the
percentage of apoptotic cells per total number of pan-
creatic cells, determined by the quantification of nuclei
stained in blue with Hoechst 33342.
Quantification All sections from each pancreatic rudiment
were digitised using cooled, three-charge-coupled-device
cameras (Hamamatsu, Middlesex, NJ, USA) linked to a
fluorescence microscope (Leitz DMRB; Leica, Rueil-
Malmaison, France). On every image, the surface area of
each staining was quantified using ImageJ 1.34 s and
summed to obtain the total surface area per explant in
mm2 as previously described [9, 23]. To quantify the prolif-
eration of early PDX1-positive pancreatic progenitors, we
counted the frequency of BrdU-positive nuclei among 2,000
early PDX1-positive progenitors per rudiment. A similar
analysis was performed in order to quantify the proliferation
of insulin-positive cells. In order to determine the rate of cell
proliferation in pancreases cultured in the presence of glu-
cose or xylitol alone, or supplemented with okadaic acid or
calyculin A, we determined the percentage of BrdU-positive
cells among all pancreatic cells. At least four explants grown
under each set of culture conditions were analysed. Results
are expressed as means±SEM.
RNA extraction and real-time PCR Total RNA was
extracted from pools of three pancreases using an RNeasy
Microkit (Qiagen, Courtaboeuf, France) and reverse-
transcribed using SuperScript reagents (Invitrogen). RT-
PCR was performed using the 7300 Fast RT-PCR system
(Applied Biosystems, Courtaboeuf, France). Oligonucleo-
tide sequences are available upon request. Peptidylpropyl
isomerase A was used as endogenous control, and E16.5
pancreas cDNA was used as calibrator sample. Data were
analysed by the comparative CT method and presented as
the fold change in gene expression normalised to an E16.5
calibrator that equalled a value of 1 [9]. At least three pools
of explants were analysed per condition, and the results are
expressed as means±SEM.
Statistics Results are expressed as means±SEM. Statistical
significance was determined using the Student’s t test when
only two sets of data were compared. For larger analyses, a
non-parametric Kurskal and Wallis test was performed, fol-
lowed by a Mann–Whitney U test.
Results
Expression of the transcription factor ChREBP during
pancreatic development We first analysed the ChREBP
expression pattern during pancreatic development. ChREBP
mRNA was detected in vivo in the pancreas as early as
E13.5, its expression gradually increasing at E15.5, E16.5
and E18.5, following a pattern that resembled the one found
for Ins and amylase mRNA (Fig. 1a–c). ChREBP levels
decreased sharply in pancreases from Neurog3-deficient
mice, indicating that its expression was highly enriched in
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the endocrine pathway (Fig. 1d). In an in vitro model of
pancreatic development in which acinar and endocrine cells
developed from E13.5 pancreases [18], ChREBP expression
level increased as cell differentiation occurred (Fig. 1f).
Xylitol and glucose treatments induce the expression of
ACCase (also known as Acaca) and L-PK (also known as
Pklr), two direct targets of ChREBP We first tested the
effect of xylitol and glucose on the expression of ACCase
and L-PK mRNA, two direct targets of ChREBP. Xylu-
lose 5-phosphate, an intermediate of the non-oxidative
branch of the pentose phosphate pathway, activates PP2A,
which will dephosphorylate and activate ChREBP [24]. Treat-
ment with either glucose or xylitol, a precursor of xylulose
5-phosphate, can thus activate ChREBP [25]. In E13.5 rat
pancreases in culture, both xylitol and glucose induced
ACCase and L-PK mRNA levels (Fig. 2). This induction
occurred in a glucose dose-dependent manner (see electronic
supplementary material [ESM] Fig. 1).
Treatment with okadaic acid, a PP2A inhibitor, re-
versed xylitol-induced activation of ACCase and L-PK ex-
pression, an effect that was stronger at 2 nmol/l than at
0.02 nmol/l (Fig. 2). Such an effect was also observed with
calyculin A, another PP2A inhibitor (data not shown). Inter-
estingly, okadaic acid treatment also reversed glucose-induced
activation of ACCase and L-PK expression, but the effect was
observed only with 2 nmol/l okadaic acid (Fig. 2).
Glucose and xylitol treatments activate beta cell develop-
ment As we observed that the expression of ChREBP tar-
gets was induced in response to either glucose or xylitol, we
analysed their effects on pancreatic development. To this
end, E13.5 rat pancreases were cultured for 7 days in medium
without added glucose (control medium) or with glucose
(10 mmol/l) or xylitol (3 and 10 mmol/l). Xylitol treatment
modified neither pancreatic morphology nor the size of the
tissue as quantified following Hoechst staining, nor acinar
cell development measured after amylase staining (Fig. 3).
Fig. 1 Levels of the transcription factor ChREBP during pancreatic
development. RT-PCR quantification of ChREBP (a), Ins (b) and
amylase (c) mRNA in the pancreas at various stages of embryonic
development (E13.5, E15.5, E16.5 and E18.5). (d,e) RT-PCR quanti-
fication of Neurog3 and ChREBP mRNA in E18.5 pancreases of wild
type or Neurog3–/– mice. (f) RT-PCR quantification of ChREBP
mRNA in E13.5 rat pancreases before (day 0) and after 1, 3, 5 and
7 days of culture. All values are means±SEM of minimum three
independent experiments. *p<0.05
Fig. 2 Effect of glucose, xylitol or okadaic acid treatment on the expres-
sion of ACCase and L-PK, two ChREBP targets. (a,b) Quantification by
RT-PCR of ACCase (a) and L-PK (b) mRNAs after 7 days of culture of
E13.5 rat pancreases in the presence or absence of xylitol (10 mmol/l),
glucose (10 mmol/l) and okadaic acid (2 or 0.02 nmol/l). Values are
means±SEM of three independent experiments. **p<0.01 compared
with pancreases cultured without glucose. †p<0.05 and ††p<0.01 when
compared with pancreases cultured without okadaic acid
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However, xylitol increased the development of insulin-
producing beta cells, as was the case for glucose, as measured
after insulin immunostaining (Fig. 3b–e). This increase in
insulin level was observed at both 3 and 10 mmol/l xylitol,
and 10 mmol/l xylitol was chosen for subsequent experiments.
Insulin-positive cells that developed in the presence of
xylitol produced beta cell markers such as the transcription
factor PDX1, an insulin gene transactivator, the pro-convertase
1/3, implicated in proinsulin processing, and synaptophysin, a
protein present on the endocrine pancreatic secretory granule
membrane (ESM Fig. 2). Such results support the fact that
insulin-positive cells that developed in the presence of xylitol
are indeed beta cells.
Glucose and xylitol treatments do not affect pancreatic cell
proliferation Our data indicate that xylitol treatment in-
creased beta cell development. Pancreatic endocrine cells
derive from early proliferating pancreatic progenitors pro-
ducing the transcription factor PDX1 [26, 27]. We first
asked whether xylitol increased beta cell mass by acting
on the proliferation of either PDX1-positive pancreatic pro-
genitors or mature beta cells. E13.5 pancreases were cul-
tured for 1 or 7 days, BrdU being added during the last hour
of culture. In control conditions, 28.45±0.57% of PDX1-
positive cells and 2.39±0.35% of insulin-positive cells in-
corporated BrdU after 1 and 7 days of culture, respectively
(ESM Fig. 3). Thus, neither xylitol nor glucose treatment
modified rates of proliferation.
Glucose and xylitol treatments promote beta cell differenti-
ation by activating the transition between Neurog3 and
NeuroD During development, PDX1-positive pancreatic
progenitors give rise to NEUROG3-positive endocrine pro-
genitors that will differentiate into beta cells [3, 28]. In control
pancreatic explants, as previously observed [9], Neurog3
mRNA levels measured by RT-PCR increased after 1 day of
culture, peaked at day 3 and decreased thereafter (Fig. 4a).
Xylitol treatment did not modify the pattern of Neurog3
expression (Fig. 4a). On the other hand, when compared with
control conditions, xylitol treatment increased the level of
NeuroD, a target of NEUROG3 necessary for proper beta cell
development (Fig. 4b) [29]. As expected based on the immu-
nohistochemical analysis performed on day 7, xylitol treat-
ment increased the INS gene expression pattern (Fig. 4c)
without modifying amylase gene expression (Fig. 4d). When
glucose was used instead of xylitol, similar effects were ob-
served on endocrine (Neurog3, NeuroD, Ins) and acinar (am-
ylase) cell development. Collectively, these results indicate
that xylitol, like glucose, acts specifically on endocrine cell
development, by controlling the transition between Neurog3
and NeuroD.
The effect of glucose and xylitol treatments on beta cell
development depends on ChREBP activation The data de-
scribed above indicate that, during pancreatic development,
xylitol induces both ChREBP activity and beta cell differ-
entiation. To determine whether the effect of xylitol on beta
Fig. 3 Glucose and xylitol activate the development of insulin-
positive cells. (a) E13.5 rat pancreases were cultured for 7 days in
the presence or absence of xylitol (3 or 10 mmol/l) or glucose
(10 mmol/l). Representative images after 1, 3 and 7 days in culture
are shown. Pancreatic epithelium is circled in white. (b) Immunohisto-
logical analysis of pancreases after 7 days of culture in the absence or
in presence of xylitol (3 or 10 mmol/l) or in the presence of glucose
(10 mmol/l). Insulin was revealed in red and amylase in green. Nuclei
are depicted in blue by Hoechst staining. The pancreatic bud is outlined
in white. Scale bar: 100 μm. (c–e) Quantification of the absolute
surface areas occupied by Hoechst-, amylase- and insulin-positive cells
after 7 days of culture in the absence or presence of xylitol or glucose
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cell differentiation was dependent on ChREBP activation,
we cultured E13.5 pancreases in medium supplemented or
not supplemented with xylitol or glucose, in the presence or
absence of okadaic acid. Okadaic acid treatment (0.02 or
2 nmol/l) did not modify pancreatic shape and growth
(Fig. 5a,b). After 7 days of culture, okadaic acid treatment
did not modify acinar cell development quantified by amy-
lase immunostaining and by RT-PCR (Fig. 5a–d). On the
other hand, the increase in beta cell development observed
with glucose or xylitol treatment was abolished by okadaic
acid treatment both at 0.02 and 2 nmol/l, as quantified by
insulin immunostaining and by RT-PCR (Fig. 5a–f). A
similar effect was observed with calyculin A (data not
shown). Importantly, PP2A inhibitors modulate neither cell
proliferation nor apoptosis (ESM Fig. 4). An alteration of
these variables can therefore not explain the observed de-
creased in beta cell mass.
To further demonstrate the role of CHREBP in beta cell
development, we infected rat embryonic pancreases with an
adenovirus producing dnChREBP [19]. For efficient infec-
tion, we dissociated E13.5 rat pancreatic cells, infected them
with adenoviruses and next reassociated the cells before
culture. We first verified that, in this assay, glucose exerted
a positive effect on beta cell differentiation, as previously
shown with undissociated pancreas [9]. This was indeed the
case as glucose induced a 2.56-fold increase in beta cell
development without modifying acinar cell development
(ESM Fig. 5).
In order to test the efficiency of gene transfer in this
model, dissociated cells were infected with an adenovirus
producing GFP. Cells were reaggregated, cultured for 2 days,
fixed and stained using an anti-GFP antibody. Almost all
cells produced GFP, demonstrating that infection was highly
efficient (data not shown). We next compared beta and
acinar cell development in pancreases that were or were
not infected with a GFP or a dnChREBP adenovirus. After
7 days of culture post-infection, the relative mass of
amylase-positive cells was similar in all three conditions
(Fig. 6a,b). On the other hand, although infection with an
adenovirus producing GFP did not modify beta cell devel-
opment, the relative number of insulin-positive cells was
reduced in pancreases infected with an adenovirus produc-
ing dnChREBP (Fig. 6a–c). Of note, the percentage of
insulin-positive cells that developed in the presence of
the adenovirus producing dnChREBP was similar to the
one obtained in reaggregated pancreases culture for 7 days
in the absence of added glucose (compare Fig. 6c and
ESM Fig. 3B).
The effect of GlcNAc treatment on beta cell development
depends on ChREBP activation We previously demon-
strated that the effect of glucose on beta cell development
was dependent on its metabolism through the HBP [11].
Specifically, in the absence of added glucose, GlcNAc, a
known substrate of the HBP, induced beta cell differentia-
tion from embryonic pancreases and thus reproduced the
effects of glucose. We therefore asked whether the effect of
GlcNAc treatment on beta cell development was also de-
pendent on ChREBP activation. Dissociated pancreases
were infected with an adenovirus producing GFP or
dnChREBP, and cultured for 7 days in the absence of
glucose but with the addition of GlcNAc 50 mmol/l. We
first verified that, in this assay, GlcNAc exerted a positive
effect on beta cell differentiation, as previously demonstrat-
ed for undissociated pancreases [11]. This was indeed the
Fig. 4 Glucose and xylitol treatments promote beta cell differentiation
by activating the transition between NEUROG3 and NeuroD. RT-PCR
quantification of Neurog3, NeuroD, Ins and amylase mRNA in E13.5
pancreases before (day 0) and after 1, 3, 5 and 7 days of culture in the
presence or absence of xylitol (10 mmol/l) or glucose (10 mmol/l).
Comparisons were performed at each time point with pancreases
cultured without glucose. Values are means±SEM of a minimum of
three independent experiments. *p<0.05; **p<0.01
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case as GlcNAc induced beta cell differentiation to the same
extent as glucose (Fig. 6c; compare the black columns).
Infection with the adenovirus producing GFP did not mod-
ify the positive effect of GlcNAc on beta cell differentiation
(Fig. 6a,c), whereas when pancreases were infected with the
adenovirus producing dnChREBP, beta cell differentiation
was reduced (Fig. 6a,c). Again, none of the conditions
modified acinar cell differentiation (Fig. 6a,b). These results
demonstrated that the positive effect of glucose and GlcNAc
on beta cell differentiation require active ChREBP.
Discussion
Pancreatic beta cell development is a multistep process. Infor-
mation is now available on the signals that regulate early steps
of the process, i.e. the development of PDX1-positive pancre-
atic progenitors from definitive endoderm [30–32]. On the
other hand, less is known about signals controlling beta cell
differentiation from PDX1-positive pancreatic progenitors.
This step in development can be further divided into three
consecutive steps: (1) the proliferation of PDX1-positive pan-
creatic progenitors; (2) their differentiation into acinar tissue
or into NEUROG3-producing endocrine progenitors; and (3)
the differentiation of NEUROG3-producing endocrine pro-
genitors into insulin-producing beta cells [33]. Here, by using
activators and inhibitors of the pentose phosphate shunt, we
demonstrated that this pathway modulated neither the pro-
liferation of PDX1-positive pancreatic progenitors, nor aci-
nar cell differentiation, nor the formation of NEUROG3-
producing endocrine progenitors. On the other hand, we
demonstrated that the positive effect of glucose and xylitol
on pancreatic beta cell differentiation depended on the
transcription factor ChREBP and occurred in NEUROG3-
producing endocrine progenitors.
In this study, we used an in vitro bioassay that recapit-
ulates the major steps occurring during beta cell develop-
ment from PDX1-positive fetal pancreatic progenitor cells.
Fig. 5 Effect of okadaic acid treatment on the expression of ACCase
and L-PK. (a) Representative images of pancreases cultured for 1, 3
and 7 days indicating that okadaic acid treatment did not modify
pancreatic shape. Pancreatic epithelium is circled in white. After 7 days
of culture, immunohistochemistry experiments were performed on the
pancreatic buds. Insulin was revealed in red and amylase in green.
Scale bar: 100 μm. (b) Quantification of the absolute surface area
occupied by Hoechst staining after 7 days of culture of 13.5 rat
pancreases in the presence or absence of xylitol (10 mmol/l), glucose
(10 mmol/l) or okadaic acid (2 or 0.02 nmol/l). (c,e) Quantification of
the absolute surface area occupied by amylase (c) and insulin staining
(e) after 7 days of culture of 13.5 rat pancreases in the presence or
absence of xylitol (10 mmol/l), glucose (10 mmol/l) or okadaic acid (2
or 0.02 nmol/l). (d,f) Quantification by RT-PCR of amylase (d) and Ins
(f) mRNA after 7 days of culture of 13.5 rat pancreases in the presence
or in the absence of xylitol (10 mmol/l), glucose (10 mmol/l) and
okadaic acid (2 or 0.02 nmol/l). Values are means±SEM of three
independent experiments. *p<0.05, **p<0.01 and NS compared with
pancreases cultured in the presence of glucose
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In this model, PDX1-positive pancreatic progenitors first pro-
liferate and next differentiate into endocrine or acinar tissue.
We previously validated and used this model to define factors
and conditions that regulate specific steps in beta cell devel-
opment. Specifically, with this assay, we previously demon-
strated that fibroblast growth factor 10 was an activator of the
proliferation of PDX1-positive pancreatic progenitors [18].
Here, we found that xylitol did not regulate cell proliferation
during pancreatic development, as previously shown for glu-
cose [9]. We also previously used this model of in vitro
pancreatic development to define signals and conditions that
modulate the differentiation of PDX1-positive pancreatic pro-
genitors into NEUROG3-positive endocrine progenitors. We
demonstrated that small molecules such as histone deacetylase
inhibitors [23], branched amino acids [34] and oxygen tension
[7] regulate the development of NEUROG3-positive endo-
crine progenitors from PDX1-positive pancreatic progeni-
tors. Recently, using the same assay, we demonstrated that
glucose regulates the next step in beta cell development,
i.e. the differentiation of beta cells from NEUROG3-
positive endocrine progenitors, and that glucose metabolism
was implicated in this regulation at least in part through
activation of the HBP [9, 11].
In the present study, we demonstrated that the transcription
factor ChREBP regulates beta cell differentiation. ChREBP
regulates gene transcription in response to glucose (for a re-
view, see [24]). Specifically, the pentose phosphate pathway,
and particularly xylulose 5-phosphate, selectively activates
PP2A, which in turn dephosphorylates the transcription factor
ChREBP [14]. This allows ChREBP translocation into the
nucleus and activation of ChREBP targets, such as the glyco-
lytic gene L-PK [35] or the lipogenic genes ACCase and Fas
(which encodes fatty acid synthase) [36]. ChREBP production
is most abundant in liver, and is small in kidney and white and
brown adipose tissue [16]. In adult islets, ChREBP controls the
expression of a number of genes such as L-PK [37], ACCase
[38], Fas [39], thioredoxin-interacting protein [40] and aryl
hydrocarbon receptor nuclear translocator [41]. Interestingly,
recent data suggest that ChREBP can also be activated by
glucose 6-phosphate [42] and by the HBP [43, 44], placing
ChREBP at the crossroads of all glucose metabolic pathways.
Little information has been available on the role of ChREBP
during pancreatic development. Different arguments derived
from the present study indicate that ChREBP is important for
proper beta cell differentiation. First, as described in this study,
ChREBP is expressed in the pancreas during development
[45]. Second, during prenatal life, ChREBP is highly enriched
in the endocrine pathway, as demonstrated by its sharp decrease
in pancreases from Neurog3-deficient mice that lack endocrine
cells. ChREBP can thus be added to the list of genes whose
expression is enriched in pancreatic endocrine cells [46]. Third,
in the embryonic pancreas, xylitol, a precursor of xylulose 5-
phosphate and an intermediary molecule of the pentose phos-
phate pathway, activates the expression of ACCase and L-PK,
two direct targets of ChREBP, demonstrating that this pathway
is functional during pancreatic development. Fourth, xylitol
activates beta cell differentiation without affecting acinar cell
development. This fits well with the fact that ChREBP is highly
enriched in cells of the endocrine pathway. In addition, okadaic
acid and calyculin A, two inhibitors of the serine/threonine
PP2A, which inhibit ChREBP activity [47, 48], suppress the
effects of xylitol on beta cell development. Finally, the produc-
tion of dnChREBP suppresses the effects of both glucose and
GlcNAc, a substrate of the HBP, on beta cell development.
Taken together, such data demonstrate that ChREBP tightly
regulates beta cell development.
We have recently demonstrated that the HBP mediates, at
least in part, the effect of glucose on beta cell differentiation
Fig. 6 Ad-dnChREBP blocks the effect of glucose and GlcNAc on
beta cell development. E13.5 rat pancreases were dissociated, infected
or not infected with Ad-GFP or Ad-dnChREBP, reaggregated and
cultured in the presence of glucose (10 mmol/l) or in the presence of
GlcNAc (50 mmol/l). (a) Immunohistological analysis of pancreases
after 7 days of culture. Insulin was revealed in red and amylase in
green. Nuclei were stained blue using a Hoechst dye. Scale bar:
100 μm. (b) Quantification of the relative surface area occupied by
amylase-positive cells after 7 days of culture. Values were normalised
to the condition ‘not infected and culture in presence of glucose
10 mmol/l’. (c) Quantification of the relative surface area occupied
by insulin-positive cells after 7 days of culture. Values were normalised
to the condition ‘not infected and culture in presence of glucose
10 mmol/l. **p<0.01
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[11]. Specifically, we had proposed that the HBP controlled
an O-GlcNAcylated factor necessary for proper beta cell
differentiation [11]. It is now established that ChREBP is
O-GlcNAcylated [43, 44]. We propose that glucose controls
beta cell differentiation, by promoting ChREBP activity,
first by allowing its dephosphorylation, and second through
the HBP, which would regulate ChREBP O-GlcNAcylation.
These two steps, controlled by glucose, would permit efficient
beta cell differentiation. One element supporting this hypoth-
esis is the fact that, in pancreases infected with an Ad-
dnChREBP, the positive effect of GlcNAc on beta cell differ-
entiation is lost (Fig. 6). Therefore, the effect of glucose on
beta cell development, via its metabolism through the HBP,
requires an active ChREBP. ChREBP is thus at the crossroads
of the different glucose metabolic pathways regulating beta
cell differentiation from pancreatic progenitors.
The phenotype of mice deficient in ChREBP was recent-
ly analysed [16]. Such mice were glucose-intolerant, but
their pancreatic phenotype was not described. In light of
our data, it would be interesting to study pancreatic beta cell
development in such mice. It will also be interesting to
determine whether glucose, through ChREBP activation,
controls human beta cell differentiation. Such information
would be important in protocols aiming at generating human
beta cells from stem cells.
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